Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nevin John

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Brain and Behavior|November 27, 2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg TestSean Apap Mangion, Charles Wade, Tom Williams, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 24, 2018
Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic eraDavid S Lynch, Charles Wade, Anderson Rodrigues Brandão de Paiva, et al.
European Journal of Neurology|June 15, 2023
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.
Neuroimage. Reports|September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
BMJ Open Sport & Exercise Medicine|February 25, 2026
Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MSLisa Grech, Belinda Beck, David Scott, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Neurology|March 12, 2022
Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple SclerosisAlberto Calvi, Ferran Prados Carrasco, Carmen Tur, et al.
Brain and Behavior|November 27, 2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg TestSean Apap Mangion, Charles Wade, Tom Williams, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 24, 2018
Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic eraDavid S Lynch, Charles Wade, Anderson Rodrigues Brandão de Paiva, et al.
European Journal of Neurology|June 15, 2023
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
Annals of Clinical and Translational Neurology|July 29, 2024
The clinical relevance of MOG antibody testing in cerebrospinal fluidMolly Reynolds, Irene Tan, Kristy Nguyen, et al.
Neuroimage. Reports|September 27, 2024
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trialThomas Williams, Nevin John, Alberto Calvi, et al.
The Lancet. Neurology|January 26, 2020
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trialJeremy Chataway, Floriana De Angelis, Peter Connick, et al.
BMJ Open|September 1, 2018
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosisPeter Connick, Floriana De Angelis, Richard A Parker, et al.
BMJ Open Sport & Exercise Medicine|February 25, 2026
Clinician-led, single-blind, randomised controlled trial evaluating the efficacy of a high-intensity resistance and impact training intervention for improving health-related quality of life in people with multiple sclerosis: protocol for STRONG-MSLisa Grech, Belinda Beck, David Scott, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Pageof 5